Open AccessReversion and Conversion of Interferon-γ Release Assay Results in HIV-1–Infected Individuals
Author(s) -
Maximilian C. Aichelburg,
Thomas Reiberger,
F Breitenecker,
Mattias Mandorfer,
Athanasios Makristathis,
Armin Rieger
Publication year - 2013
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jit418
Subject(s) - reversion , human immunodeficiency virus (hiv) , interferon gamma release assay , virology , medicine , tuberculosis , interferon , incidence (geometry) , prospective cohort study , viral disease , immunology , biology , mycobacterium tuberculosis , latent tuberculosis , pathology , gene , biochemistry , physics , optics , phenotype
In this prospective study, human immunodeficiency virus type 1 (HIV-1)-infected subjects underwent QuantiFERON-TB Gold In-Tube interferon-γ release assay (IGRA) testing at baseline and after 24 months in a low tuberculosis incidence country. Concordant baseline and follow-up results were observed in 86% (n = 686 of 794) of subjects. IGRA conversions occurred in 9% (n = 63 of 718), whereas IGRA reversions were seen in 33% (n = 25 of 76) of individuals. Of the 10 active tuberculosis cases during follow-up, 5 had concordant positive IGRA results and 2 were IGRA converters. Although the clinical significance of IGRA conversions and reversions remains to be established, repeated IGRA testing seems to be of value in HIV-1-infected individuals.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom